Concerns have been raised by senior doctors surrounding the misuse of weight-loss pens in the UK, with some patients ...

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

The Biden administration has announced a new proposal to include weight-loss drugs under Medicare and Medicaid programmes. While the plan will help more than seven million Americans struggling with ...

Shares of Eli Lilly LLY and Novo Nordisk NVO were up on Tuesday, likely due to a proposal by President Biden that Medicare ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The Department of Health and Human Services seeks to expand when Medicare and Medicaid can cover anti-obesity drugs, such as ...